KMT2A rearrangements are known to have an unfavorable prognosis in AML, and the specific t(6;11)(q27;23) translocation in AML patients leads to a median overall survival of only 12 months (Berg et al., 2022; Schuy et al., 2022). This evidence concerns the gene KMT2A and acute myeloid leukemia.